Crocetti Letizia, Giovannoni Maria Paola, Pavlov Tengis S, Ivanov Veniamin, Melani Fabrizio, Guerrini Gabriella
Neurofarba, Pharmaceutical and Nutraceutical Section, University of Florence, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy.
Division of Hypertension and Vascular Research, Henry Ford Health & Wayne State University, 6135 Woodward Ave, Detroit, MI 48202, USA.
Molecules. 2025 May 15;30(10):2171. doi: 10.3390/molecules30102171.
The membrane channel protein Panx1 is a promising therapeutic target since its involvement was demonstrated in a variety of pathologies such as neuropathic pain, ischemic stroke and cancer. As a continuation of our previous work in this field, we report here the synthesis and biological evaluation of two classes of compounds as Panx1 blockers: 3-carboxy-6-sulphonamidoquinolone derivatives and new Mefloquine analogs. The series of 3-carboxy-6-sulphonamidoquinolones gave interesting results, affording powerful Panx1 channel blockers with 73.2 < I% < 100 at 50 µM. In particular, was a more potent Panx1 blocker than the reference compound CBX (IC = 2.7 µM versus IC = 7.1 µM), and its profile was further investigated in a cell culture model of polycystic kidney disease. Finally, interesting results have been highlighted by new molecular modeling studies.
膜通道蛋白Panx1是一个很有前景的治疗靶点,因为它参与了多种病理过程,如神经性疼痛、缺血性中风和癌症。作为我们此前在该领域工作的延续,我们在此报告两类作为Panx1阻滞剂的化合物的合成及生物学评估:3-羧基-6-磺酰胺基喹诺酮衍生物和新型甲氟喹类似物。3-羧基-6-磺酰胺基喹诺酮系列产生了有趣的结果,在50 μM时提供了强大的Panx1通道阻滞剂,73.2 < I% < 100。特别是, 是一种比参考化合物CBX更有效的Panx1阻滞剂(IC = 2.7 μM对IC = 7.1 μM),并且在多囊肾病细胞培养模型中进一步研究了其特性。最后,新的分子模拟研究突出了有趣的结果。